**Contents**

**Highlights of This Issue**  5809

**SPECIAL FEATURES**

**CCR Translations**

5811  
**It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma**  
Arman Jahangiri and William A. Weiss  
*See related article, p. 5940*

**CCR New Strategies**

5814  
**New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK**  
Giuseppe Barone, John Anderson, Andrew D.J. Pearson, Kevin Petrie, and Louis Chesler

**CCR Perspectives in Drug Approval**

5822  
**Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases**  
Michel D. Wissing, Fijs W.B. van Leeuwen, Gabri van der Pluijm, and Hans Gelderblom

**CCR Drug Updates**

5828  
**Ponatinib—A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia**  
Olga Frankfurt and Jonathan D. Licht

**Molecular Pathways**

5835  
**Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer**  
Bo Li and M. Celeste Simon

5842  
**Molecular Pathways: Estrogen Pathway in Colorectal Cancer**  
Afshaneh Barzi, Annika Medea Lenz, Melissa J. Labonte, and Heinz-Josef Lenz

**Perspectives**

5849  
**The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis**  
Kenneth J. Pienta, Bruce A. Robertson, Donald S. Coffey, and Russell S. Taichman

**Review**

5856  
**Targeting Fibroblast Growth Factor Pathways in Prostate Cancer**  
Paul G. Corn, Fen Wang, Wallace L. McKeelhan, and Nora Navone

**HUMAN CANCER BIOLOGY**

5867  
**Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization**  
Zhi-Zhou Shi, Li Zhang, Yan-Yi Jiang, Miao Jie Hao, Yu Zhang, Tong-Tong Zhang, De-Chen Lin, Shu-Guang Liu, Bo-Shi Wang, Ting Gong, Qi-Min Zhan, and Ming-Rong Wang

5879  
**Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma**  

5890  
**Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features**  
Fortunato Morabito, Laura Mosca, Giovanni Cutrona, Luca Agnelli, Giacomo Tuana, Manuela Ferracin, Barbara Zagatti, Marta Lionetti, Sonia Fabris, Francesco Maura, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Carlotta Massucco, Anna Grazia Becchia, Sabrina Bossio, Laura De Stefano, Fiorella Ilariucci, Caterina Musolin, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzu, Pierfrancesco Tassone, Massimo Negrini, Sara Monti, Davide Rossi, Gianluca Gaidano, Manlio Ferrari, and Antonino Neri

**Clinical**

November 1, 2013 • Volume 19 • Number 21
Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature

Mercedes Herrera, Abul B.M.M.K. Islam, Alberto Herrera, Paloma Martín, Vanesa García, Javier Silva, Jose M. García, Clara Salas, Ignacio Casal, Antonio García de Herreros, Félix Bonilla, and Cristina Peña

A Negative Feedback of the HIF-1α Pathway via Interferon-Stimulated Gene 15 and ISGylation

Yen-Hsiu Yeh, Yu-Chen Yang, Mei-Yi Hsieh, Yen-Cheng Yeh, and Tsai-Kun Li

CANCER THERAPY: PRECLINICAL

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo


See related article, p. 5811

DNA Demethylating Agents Synergize with Oncolytic HSV1 against Malignant Gliomas

Kazu Okemoto, Kazue Kasai, Benjamin Wagner, Amy Haseley, Hans Meisen, Chelsea Bolyard, Xiaoqin Mo, Allison Wehr, Amy Lehman, Soledad Fernandez, Balveen Kaur, and E. Antonio Chiocca

Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer


Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

Libo Zhang, Paula Marrano, Sushil Kumar, Michael Leadley, Evelyn Elias, Paul Thorner, and Sylvain Baruchel
Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs
Kehua Wu, Larry House, Jacqueline Ramirez, Michael J. Seminerio, and Mark J. Ratain

LETTER TO THE EDITOR
Aflibercept and Its Role in the Treatment of Colorectal Cancer—Letter
Frank A. Sinicrope, Eric E. Williamson, and Daniel D. Borgeson

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
Barbara Pardini, Fabio Rosa, Elisa Barone, Cornelia Di Gaetano, Jana Slyskova, Jan Novotny, Miroslav Levy, Sonia Garritano, Ludmila Vodickova, Tomas Buchler, Federica Gemignani, Stefano Landi, Pavel Vodicka, and Alessio Naccarati

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER
The cover shows primary cultures of CAFs from colorectal cancer patients: immunofluorescence analyses for α-SMA expression in human primary colon CAFs from two different patients with low and high α-SMA level. For details, see the article by Herrera and colleagues on page 5914 of this issue.
Clinical Cancer Research

19 (21)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/21

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.